section name header

Evidence summaries

Parp (Poly Adpribose Polymerase) Inhibitors for Locally Advanced or Metastatic Breast Cancer

Poly ADP-ribose polymerase inhibitors (PARPi) appear to be effective for progression-free survival in locally advanced or metastatic breast cancer compared with no PARPi treatments. Level of evidence: "B"

The certainty of evidence is downgraded by study limitations (unclear allocation concealment in half of the studies).

Summary

A Cochrane review [Abstract] 1 included 5 studies with a total of 1474 subjects with breast cancer. There was a clear trend of small advantage in overall survival with poly ADP-ribose polymerase inhibitors (PARPi). In locally advanced/metastatic HER2-negative, BRCA germline mutated breast cancer, PARPi offer an improvement in progression-free survival (PFS), table T1. There was no statistical heterogeneity for these outcomes. Subgroup analyses for PFS outcomes based on trial level data were performed for triple-negative breast cancer, hormone-positive and/or HER2-positive breast cancer, and BRCA1 and BRCA2 germline mutations.

PARPi-containing regimen compared to non-PARPi regimen for locally advanced or metastatic breast cancer

OutcomeRelative effect (95% CI)Risk with controlRisk with intervention (PARPi)No of subjects (studies) Quality of evidence
Overall Survivalfollow up: 24 monthsHR 0.84(0.76 to 1.00)550 per 1000497 per 1000(446 to 550)1435(4) Moderate
Progression Free Survivalfollow up: 12 monthsHR 0.63(0.56 to 0.71)625 per 1000461 per 1000(423 to 502)1474(5) High
Response RateRR 1.39(1.24 to 1.54)489 per 1000695 per 1000(636 to 749)1185(5) Low
Grade (severity al least 3) of adverse effectsRR 0.98(0.91 to 1.04)645 per 1000620 per 1000(555 to 684)1443(5) Moderate

Clinical comments

Note

Date of latest search: 2022-02-14

References

  • Taylor AM, Chan DLH, Tio M et al. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. Cochrane Database Syst Rev 2021;(4):CD011395. [PubMed]

Primary/Secondary Keywords